Clinical Trials Browser

Phase 1/2 × Mesothelioma × 90 days × Clear all

Glioblastoma, Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT05579366 2026-04-07

RAINFOL-01

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05732831 2026-04-06

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Phase 1/2 Recruiting

225 enrolled

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT07510815 2026-04-06

DUAL-MESO-NK

Phase 1/2 Recruiting

36 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT04665206 2026-04-02

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Phase 1/2 Recruiting

434 enrolled

Other solid neoplasmThoracic

Mesothelioma

NCT06051695 2026-02-20

EVEREST-2

Phase 1/2 Recruiting

474 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Colorectal Neoplasms

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Clinical Trials

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

RAINFOL-01

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

DUAL-MESO-NK

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

EVEREST-2

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors